<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metronidazole and nystatin (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metronidazole and nystatin (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Metronidazole and nystatin (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11503" href="/d/html/11503.html" rel="external">see "Metronidazole and nystatin (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52928977"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Flagystatin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F2530154"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antifungal Agent, Vaginal;</li>
<li>
                        Antiprotozoal, Nitroimidazole</li></ul></div>
<div class="block doa drugH1Div" id="F2530192"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a583c82e-c97f-49d0-a43c-f52750a7e2d0">Vaginal infection, mixed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vaginal infection, mixed:</b> Females: <b>Intravaginal:</b> Vaginal tablet (ovule): Insert 1 tablet daily at bedtime for 10 consecutive days. May repeat for an additional 10 days if cure is not achieved.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Applicator should not be used after the seventh month of pregnancy. If <i>T. vaginalis</i> is not completely eliminated, oral (systemic) metronidazole should be administered.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990179"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987542"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; however, a reduced dose is recommended with severe impairment.</p></div>
<div class="block adr drugH1Div" id="F2530163"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash (located around the knee), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Coated tongue, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vaginal discomfort (granular sensation), vulvovaginal burning</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Bitter taste, fatigue, headache</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (including ankles, wrists), joint swelling (including ankles, wrists)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Decreased visual acuity, diplopia, myopia, vision color changes</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Suicidal ideation</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuritis, optic neuropathy</p></div>
<div class="block coi drugH1Div" id="F2530159"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to metronidazole, nystatin, imidazoles, or any component of the formulation. Combined treatment with oral metronidazole should be avoided in active neurological disorders or in patients with a history of blood dyscrasia, hypothyroidism, or hypoadrenalism.</p>
<p style="text-indent:-2em;margin-left:2em;">Also refer to Metronidazole (Systemic) monograph.</p></div>
<div class="block war drugH1Div" id="F2530160"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Carcinogenic: Metronidazole is possibly carcinogenic based on animal data.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Central or peripheral neuropathy may occur with metronidazole treatment. Consider discontinuation of therapy if ataxia or other CNS signs/symptoms occur; use with caution in patients with CNS disease. CNS signs/symptoms may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Severe cutaneous adverse reactions, including acute generalized exanthematous pustulosis, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported. If a reaction occurs, discontinue immediately and consider further evaluation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Local effects: Local irritation/sensitivity have been reported; if irritation occurs, discontinue therapy and institute appropriate treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric effects: Suicidal ideation with or without depression has been reported with use. Discontinue use immediately if psychiatric symptoms occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Discontinue use and administer alternative therapy if superinfection occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic effects: Systemic absorption of metronidazole from vaginal administration may occur. Adverse effects normally associated with systemic administration of metronidazole may occur following the vaginal administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urine discoloration: Patients should be informed that urine may become darker in color.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cockayne syndrome: <b>[Canadian Boxed Warning]: Cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome, with very rapid onset after treatment initiation, in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use. In this population, metronidazole and nystatin should, therefore, only be used after careful benefit-risk assessment and only if no alternative treatment is available. </b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with severe hepatic impairment due to potential accumulation; dosage adjustment is recommended in these patients. Use caution in patients with hepatic encephalopathy and in patients with a history of livery injury associated with metronidazole.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sexual partners: Sexual partners should receive concurrent treatment (oral metronidazole) when there is evidence of trichomonal infestation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Vaginal products: May limit the effectiveness of diaphragms and condoms; concurrent use with treatment is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Alcohol consumption: Disulfiram-like reactions to ethanol have been reported with systemic metronidazole and may occur with topical metronidazole; consider avoidance of alcoholic beverages during therapy with topical products and for at least 1 day after.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: May not be effective in bacterial vaginal infections and should not be prescribed unless there is direct evidence of trichomonal infestation or candidiasis. Candidiasis confirmation should be followed up with identification of promoting factors so they can be offset or eliminated. It is recommended that treatment of <i>Candida</i> involve all associated sites concurrently (intestinal, vaginal, or other infections). Risk of developing resistant organisms is increased if prescribed without evidence or strong suspicion of a mixed vaginal infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fungal replication: Use of soaps with an acid pH, vaginal injections, and tampons may promote fungal replication and should be avoided during treatment.</p></div>
<div class="block prod-avail drugH1Div" id="F11234082"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the United States.</p></div>
<div class="block geq drugH1Div" id="F52931796"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F52928978"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suppository, Vaginal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flagystatin: metronidazole 500 mg and nystatin 100,000 units (1 ea)</p></div>
<div class="block adm drugH1Div" id="F28842960"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Intravaginal: For vaginal use only. Use only the applicator provided with the product for administration. Pull applicator plunger back about one inch and insert a tablet into the cup at the end of the hollow tube. Administer one applicator with tablet intravaginally. Lie on back with knees drawn up. Insert applicator gently into the vagina as far as possible without causing discomfort. Press the plunger after it is in proper position in the vagina; withdraw the applicator. Wash applicator in warm water after use. Patients should not use intravaginal products (eg, tampons, douches) for the duration of treatment.</p></div>
<div class="block use drugH1Div" id="F2530155"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Vaginal infection, mixed:</b> Treatment of mixed vaginal infection due to <i>Trichomonas vaginalis</i> and <i>Candida albicans.</i></p></div>
<div class="block mst drugH1Div" id="F56915239"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>ALERT: Canadian Boxed Warning:</b> Health Canada–approved labeling includes a boxed warning. See "Warnings/Precautions" section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299706"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F2530185"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.  Management: Warn patients and monitor for signs and symptoms of a disulfiram-like reaction if patients consume alcohol while using topical metronidazole. Some manufacturers of vaginal metronidazole products list alcohol use within 24 to 72 hours as a contraindication<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Disulfiram. In particular, the risk for CNS toxicities such as psychosis may be increased.  Management: Warn patients and monitor for the development of serious CNS toxicity if topical metronidazole is used in a patient taking disulfiram. Some manufacturers of vaginal metronidazole products list disulfiram use within 2 weeks as a contraindication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Lopinavir. Specifically, the use of topical metronidazole with lopinavir/ritonavir solution (which contains 42% alcohol) may result in a disulfiram-like reaction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Progesterone: Antifungal Agents (Vaginal) may diminish the therapeutic effect of Progesterone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Tipranavir. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308223"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">This combination product may decrease the effectiveness of condoms or diaphragms; other forms of contraception should be used during therapy. Also refer to individual monographs.</p></div>
<div class="block pri drugH1Div" id="F2530156"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Metronidazole crosses the placenta; information for nystatin is not available although systemic absorption is unlikely. The manufacturer does not recommend use of metronidazole during the first trimester of pregnancy or use of this combination product with the applicator after the seventh month of pregnancy. Also refer to individual monographs.</p></div>
<div class="block brc drugH1Div" id="F11233710"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Metronidazole is present in breast milk; information for nystatin is not available although systemic absorption is unlikely. The manufacturer of this combination product recommends that use in breastfeeding women be avoided. Also refer to individual agents.</p></div>
<div class="block mop drugH1Div" id="F56556959"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">LFTs (patients with Cockayne syndrome); total and differential leukocyte counts (before and after treatment, particularly if a second course of metronidazole is necessary); mental status; neurologic symptoms; dermatologic reactions.</p></div>
<div class="block pha drugH1Div" id="F2530189"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block phk drugH1Div" id="F13270998"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869468"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Farm x duo | Flagystatin | Metanis | Pelvicillin nf</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Flagyl nistatina</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Nistatina metronidazol</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Duovagin | Flagyl | Flagyl nistatina | Metronidazol + nistatina | Metronidazol + Nistatina MK | Metronidazol / nistatina | Metronist | Metrozin nistatina</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Acromona | Candistatin M | Cryozol N | Dimezol | Fraginal N | Karynistin M | Livagin M | Metanis | Metricol n | Metrocaps N | Metrofar Compuesto | Metromona | Metronidazol + nistatina | Metronidazol+ Nistatina | Mevagin | Nistamet | Nistazole Plus | Obsteclox | Ovil m | Ovugel M | Ovulrinat | Vildo N</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acromona | Feminal | Metronidazol + nistatina | Tricom N</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Amrizole n</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Flagyl comp</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Fladystin | Flagystatin | Neo Gynoxa | Provagin | Trichodazol plus | Trichostatic | Vagistin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Fedystat | Fenimeth V | Flagenase vg | Flagystatin v | Metrofur | Metroson-v | Vanestrin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Flagystatine | Gino fungistat | Nistafem | Nistatina + mtronidazol | Vaxigel</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Flagystatin</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Flagystatin | Ginetric | Metanis | Tricolan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Nystazole</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Flagystatin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Flagystatin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Metricol n | Metronidazol + nistatina | Ovil m</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Flagystatin (metronidazole and nystatin) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; May 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10210 Version 98.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
